We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Draft Policy Calls for ‘Considered Approach’ on Trial Transparency
EMA Draft Policy Calls for ‘Considered Approach’ on Trial Transparency
July 10, 2013
The European Medicines Agency last month unveiled its proposed policy for increasing access to clinical trial data, offering a “considered approach” to transparency that respects patient and commercial interests.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor